arrow
Κ

Κατερίνα Αντωνίου

University of Crete
H指数:57
被引数:1.3万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Mepolizumab long-term remodeling effect in severe asthma responders: the MESILICO study.

美泊利单抗在重症哮喘应答者中的长期重塑效应:MESILICO研究。

2026-09-280
OAAI
ERS/EULAR clinical practice guidelines for connective tissue disease-associated interstitial lung disease

欧洲呼吸学会(ERS)/欧洲风湿病学会联盟(EULAR)结缔组织病相关间质性肺疾病临床实践指南由欧洲呼吸学会(ERS)和欧洲风湿病学会联盟(EULAR)结缔组织病相关间质性肺疾病工作组制定欧洲罕见呼吸疾病参考网络(ERN-LUNG)认可

2026-01-0120
OA
Reply: The rationale for distinguishing RB-ILD and AMP

回复:区分RB-ILD和AMP的依据

2025-12-011
PRE
Reply: Bronchiolocentric interstitial pneumonia is a morphological term used for lung biopsy and chest imaging pattern and is not a substitute for hypersensitivity pneumonitis

回复:细支气管中心性间质性肺炎是一个用于肺活检和胸部影像学模式的形态学术语,它并不是过敏性肺炎的替代术语。

2025-12-010
PRE
Update of the international multidisciplinary classification of the interstitial pneumonias: an ERS/ATS statement

Ryerson, C.J.; Adegunsoye, A.; Piciucchi, S.; Hariri, L.P.; Khor, Y.H.; Wijsenbeek, M.S.; Wells, A.U.; Sharma, A.; Cooper, W.A.; Antoniou, K.; et al. 间质性肺炎的国际多学科分类更新:ERS/ATS声明。Eur. Respir. J. 2025, 2500158. [Google Scholar] [CrossRef] [PubMed]

2025-12-0133
PRE
Club cell secretory protein (CC16) polymorphisms in preterm neonates with respiratory distress syndrome and bronchopulmonary dysplasia

Club cell secretory protein (CC16)多态性在呼吸窘迫综合征和支气管肺发育不良的早产新生儿中的研究

2025-05-150
OA
Clinical remission in patients with severe eosinophilic asthma treated with mepolizumab: A post-hoc analysis of RELIght study

重度嗜酸性哮喘患者接受美泊利单抗治疗后的临床缓解:RELight研究的事后分析

2025-01-011
PRE
Disease trajectory of newly diagnosed patients with pulmonary fibrosis using online home spirometry in the international multicenter I-FILE study
2024-10-300
PRE
Effectiveness of Mepolizumab in patients with late-onset severe eosinophilic asthma and fixed obstruction, a 2-Year Follow-Up: The MESILICO study
2024-10-300
PRE
The REALISM Study: The Experience of Pulmonologists with Benralizumab in Greece
2024-10-300
PRE
Clinical remission in patients with severe eosinophilic asthma treated with mepolizumab:a post-hoc analysis of the 2-year RELIght study
2024-10-300
PRE
Lung Ultrasound as a Screening Tool for Subclinical Rheumatoid Arthritis-Associated Interstitial Lung Disease
2024-10-300
PRE
Calprotectin serum levels on admission and during follow-up predict severity and outcome of patients with COVID-19: A prospective study
2024-04-011
PRE
Switching from omalizumab to mepolizumab in severe asthmatics: A post hoc analysis of the RELight study
2023-12-120
PRE
The clinical experience of patients with severe asthma and previous treatment with omalizumab, choosing mepolizumab in Greece.
2023-10-270
PRE